CG Oncology posts Q2 2026 loss, boosts stock program
CG Oncology, Inc. reported second quarter 2026 results and expanded its equity financing capacity.
Rhea-AI Filing Summary
CG Oncology, Inc. reported second quarter 2026 results and expanded its equity financing capacity. For the quarter ended June 30, 2026, total revenues were $1,157 thousand and net loss was $79,056 thousand, or $0.90 per share, driven mainly by higher research and development and general and administrative expenses.
Cash, cash equivalents and marketable securities totaled approximately $1.0 billion as of June 30, 2026, which the company expects will fund operations through 2029. CG Oncology continues late‑stage development of cretostimogene grenadenorepvec, with Phase 3 PIVOT‑006 topline data anticipated in the near term and completion of a BLA for high‑risk BCG‑unresponsive NMIBC targeted for the fourth quarter of 2026. Phase 3 BOND‑003 Cohort C results were published in The Lancet Oncology, and a Delaware court denied ANI’s post‑trial motions, leaving in place a prior jury verdict favorable to CG Oncology.
Separately, CG Oncology filed Amendment No. 2 to its prospectus under an Open Market Sale Agreement with Jefferies, increasing the amount of common stock that may be sold under the at‑the‑market program by up to $500.0 million, after previously registering and selling approximately $550.0 million of shares.
Positive
- None.
Negative
- None.
Filing Explained
The August 6 8-K records an amendment adding up to
8-K Event Classification
Key Figures
Key Terms
Open Market Sale Agreement financial
Registration Statement on Form S-3ASR regulatory
BLA regulatory
oncolytic immunotherapy medical
non-muscle invasive bladder cancer (NMIBC) medical
BCG-unresponsive medical
Earnings Snapshot
The company states its existing cash, cash equivalents and marketable securities as of June 30, 2026 will be sufficient to fund operations through 2029.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were CGON’s key financial results for the quarter ended June 30, 2026?
What is CGON’s cash position and runway after Q2 2026?
How did CGON change its at-the-market stock sale program?
What are the key clinical milestones CGON highlighted for cretostimogene?
What regulatory or legal developments affecting CGON were disclosed?
What recent data publications support CGON’s cretostimogene program?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, CG Oncology, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
On August 6, 2026, the Company filed Amendment No. 2 to Prospectus (the “Amendment No. 2”) with the Securities and Exchange Commission (the “SEC”) for the offer and sale of shares of its common stock, par value $0.0001 per share (the “Shares”), pursuant to that certain Open Market Sale Agreement, dated March 28, 2025, by and between the Company and Jefferies LLC (the “Sale Agreement”), to increase the Shares available to be sold pursuant to the terms of the Sale Agreement by an additional $500.0 million (the “Additional Shares”). The Amendment amends and supplements the information in the prospectus dated March 28, 2025 (the “Prospectus”) filed with the SEC as part of the Company’s Registration Statement on Form S-3ASR (File No. 333-286230) and Amendment No. 1 to Prospectus dated January 13, 2026 (the “Amendment No. 1”), pursuant to which the Company previously registered and sold approximately $550.0 million of shares of the Company’s common stock pursuant to the Sale Agreement.
The Amendment should be read in conjunction with the Prospectus and Amendment No. 1, and is qualified by reference thereto, except to the extent that the information therein amends or supersedes the information contained in the Prospectus and Amendment No. 1. The Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus, Amendment No. 1 to Prospectus and any future amendments or supplements thereto.
A copy of the opinion of Cooley LLP relating to the validity of the Additional Shares is attached as Exhibit 5.1 hereto.
Item 9.01 Financial Statements and Exhibits.
(d) |
Exhibits |
|
|
|
Exhibit No. |
|
Description |
|
|
|
5.1 |
|
Opinion of Cooley LLP |
23.1 |
|
Consent of Cooley LLP (included in Exhibit 5.1) |
99.1 |
|
Press release, dated August 6, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CG Oncology, Inc. |
|
|
Date: August 6, 2026 |
By: /s/ Josh Patterson |
|
Name: Josh Patterson |
|
Title: General Counsel and Chief Compliance Officer |
Exhibit 99.1
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
DALLAS, Texas, August 6, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates.
“This quarter we have made significant progress across our clinical, regulatory, manufacturing and commercial-readiness initiatives, positioning the Company for long-term success. PIVOT-006 has accrued the vast majority of the target events, and we look forward to sharing topline results soon. We are confident in the potential of cretostimogene and are committed to delivering what we believe will be a backbone therapy for patients,” stated Arthur Kuan, Chairman & Chief Executive Officer at CG Oncology.
|
Corporate Highlights
Anticipated 2026 Milestones
Second Quarter Financial Highlights
2
|
About Cretostimogene Grenadenorepvec
Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy that has been studied in a clinical development program, which includes more than 600 patients with Non-Muscle Invasive Bladder Cancer (NMIBC). This program includes two Phase 3 clinical trials: BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC. CG Oncology also has a multi-cohort Phase 2 trial, CORE-008, evaluating the safety and efficacy of cretostimogene in high-risk NMIBC. Additionally, we have initiated an Expanded Access Program for cretostimogene in North America for patients who are unresponsive to BCG and meet certain program eligibility requirements. Cretostimogene is an investigational candidate, and its safety and efficacy have not been established by the FDA or any other health authority.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
3
|
Forward-Looking Statements
CG Oncology cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding our anticipated cash runway, future results of operations and financial position; the anticipated timing and conduct of our ongoing and planned clinical trials and preclinical studies for cretostimogene, including anticipated next milestones in our development pipeline; the timing and likelihood of regulatory filings and approvals for cretostimogene; the potential therapeutic benefits of cretostimogene for high-risk and intermediate-risk NMIBC patients; and that cretostimogene has a best-in-disease product profile. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data becomes available; potential delays in the commencement, enrollment and completion of clinical trials, including the BOND-003 and PIVOT-006 trials; we may use our capital resources sooner than expected and they may be insufficient to allow us to achieve our anticipated milestones; our dependence on third parties in connection with manufacturing, shipping and clinical and preclinical testing; results from earlier clinical trials and preclinical studies not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval, and/or commercialization; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K and other filings that we make with the SEC from time to time (which are available at http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
4
|
Contacts:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com
Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com
5
|
CG ONCOLOGY, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(unaudited)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Commercial and development revenue |
|
$ |
1,147 |
|
|
$ |
— |
|
|
$ |
2,216 |
|
|
$ |
— |
|
License and collaboration revenue |
|
|
10 |
|
|
|
— |
|
|
|
24 |
|
|
|
52 |
|
Total revenues |
|
|
1,157 |
|
|
|
— |
|
|
|
2,240 |
|
|
|
52 |
|
Operating costs and expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of sales |
|
|
3,925 |
|
|
|
— |
|
|
|
6,887 |
|
|
|
— |
|
Research and development |
|
|
54,657 |
|
|
|
31,331 |
|
|
|
98,387 |
|
|
|
58,799 |
|
General and administrative |
|
|
28,976 |
|
|
|
17,410 |
|
|
|
49,756 |
|
|
|
32,198 |
|
Total operating costs and expenses |
|
|
87,558 |
|
|
|
48,741 |
|
|
|
155,030 |
|
|
|
90,997 |
|
Loss from operations |
|
|
(86,401 |
) |
|
|
(48,741 |
) |
|
|
(152,790 |
) |
|
|
(90,945 |
) |
Other income (expense), net: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income, net |
|
|
7,329 |
|
|
|
7,319 |
|
|
|
13,617 |
|
|
|
15,066 |
|
Other income (expense), net |
|
|
16 |
|
|
|
(4 |
) |
|
|
(85 |
) |
|
|
1 |
|
Total other income, net |
|
|
7,345 |
|
|
|
7,315 |
|
|
|
13,532 |
|
|
|
15,067 |
|
Net loss and comprehensive loss |
|
$ |
(79,056 |
) |
|
$ |
(41,426 |
) |
|
$ |
(139,258 |
) |
|
$ |
(75,878 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.90 |
) |
|
$ |
(0.54 |
) |
|
$ |
(1.61 |
) |
|
$ |
(1.00 |
) |
Weighted average shares of common stock outstanding, basic and diluted |
|
|
88,200,023 |
|
|
|
76,226,829 |
|
|
|
86,369,437 |
|
|
|
76,207,333 |
|
CG ONCOLOGY, INC.
Consolidated Balance Sheet Data
(In thousands)
|
|
|
June 30, |
|
|
December 31, |
|
||
|
|
|
2026 |
|
|
2025 |
|
||
|
|
|
(unaudited) |
|
|
|
|
||
Cash, cash equivalents, and marketable securities |
|
|
$ |
1,028,278 |
|
|
$ |
742,155 |
|
Total assets |
|
|
|
1,085,655 |
|
|
|
791,592 |
|
Total liabilities |
|
|
|
56,537 |
|
|
|
38,990 |
|
Total stockholders' equity |
|
|
|
1,029,118 |
|
|
|
752,602 |
|
6
|